The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Clovis Oncology, Inc. | Common Stock | 189464100 | 687,521 | 101,855 | SH | OTR | 0 | 101,855 | 0 | ||
| CymaBay Therapeutics, Inc. | Common Stock | 23257D103 | 1,897,697 | 543,753 | SH | OTR | 0 | 543,753 | 0 | ||
| Gritstone Oncology, Inc. | Common Stock | 39868T105 | 20,603,449 | 3,102,929 | SH | OTR | 0 | 3,102,929 | 0 | ||
| Second Sight Medical Products, Inc. | Common Stock | 81362J100 | 550,211 | 561,612 | SH | OTR | 0 | 561,612 | 0 | ||
| Ocular Therapeutix, Inc. | Common Stock | 67576A100 | 18,454,145 | 2,215,384 | SH | OTR | 0 | 2,215,384 | 0 | ||
| CRISPR Therapeutics AG | Common Stock | H17182108 | 307,413,373 | 4,183,064 | SH | OTR | 0 | 4,183,064 | 0 | ||
| Veracyte, Inc. | Common Stock | 92337F107 | 31,220,041 | 1,205,407 | SH | OTR | 0 | 1,205,407 | 0 | ||
| Adverum Biotechnologies, Inc. | Common Stock | 00773U108 | 146,241,265 | 7,003,892 | SH | OTR | 0 | 7,003,892 | 0 | ||
| Akero Therapeutics, Inc. | Common Stock | 00973Y108 | 52,717,114 | 2,115,454 | SH | OTR | 0 | 2,115,454 | 0 | ||
| Aprea Therapeutics, Inc. | Common Stock | 03836J102 | 71,907,001 | 1,854,229 | SH | OTR | 0 | 1,854,229 | 0 | ||
| Crinetics Pharmaceuticals, Inc. | Common Stock | 22663K107 | 35,576,392 | 2,030,616 | SH | OTR | 0 | 2,030,616 | 0 | ||
| IVERIC bio, Inc. | Common Stock | 46583P102 | 8,797,036 | 1,724,909 | SH | OTR | 0 | 1,724,909 | 0 | ||